A Phase Ib/II Study to Evaluate Multiple Combination Therapies of FWD1802 in Patients With ER+/HER2- BC

NCT07002177 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

196

Enrollment

INDUSTRY

Sponsor class

Conditions

Metastatic Breast Cancer
Breast Cancer Stage I
Breast Cancer Stage II
Locally Advanced Breast Cancer (LABC)
ER+ Breast Cancer

Interventions

DRUG: FWD1802
DRUG: Palbociclib 125mg
DRUG: Ribociclib 200Mg Oral Tablet
DRUG: Abemaciclib 150 MG
DRUG: Everolimus 10 mg

Sponsor

Forward Pharmaceuticals Co., Ltd.